Last Updated: November 12, 2026

Details for Patent: 11,286,486

Name: Drug Patent Intelligence for US Patent 11286486
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

Which drugs does patent 11,286,486 protect, and when does it expire?

Patent 11,286,486 protects AMVUTTRA and is included in one NDA.

This patent has sixty-three patent family members in thirty-seven countries.

Summary for Patent: 11,286,486

Title:	Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Abstract:	The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.
Inventor(s):	Tracy Zimmermann, Amy Chan, Vasant R. Jadhav, Martin A. Maier, Kallanthottathil G. Rajeev
Assignee:	Alnylam Pharmaceuticals Inc
Application Number:	US16/864,226
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,286,486
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 11,286,486

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alnylam Pharms Inc	AMVUTTRA	vutrisiran sodium	SOLUTION;SUBCUTANEOUS	215515-001	Jun 13, 2022		RX	Yes	Yes	11,286,486	⤷ Start Trial	Y	Y		AMVUTTRA IS INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,286,486

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3329002	⤷ Start Trial	301216	Netherlands	⤷ Start Trial
European Patent Office	3329002	⤷ Start Trial	PA2023505	Lithuania	⤷ Start Trial
European Patent Office	3329002	⤷ Start Trial	7/2023	Austria	⤷ Start Trial
European Patent Office	3329002	⤷ Start Trial	2023C/507	Belgium	⤷ Start Trial
European Patent Office	3329002	⤷ Start Trial	LUC00297	Luxembourg	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.